The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2020

Filed:

Sep. 07, 2018
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Silver Spring, MD (US);

Inventors:

Raj K. Puri, Potomac, MD (US);

Kathryn C. Zoon, Kensington, MD (US);

Syed R. Husain, Gaithersburg, MD (US);

Daniel S. Green, Silver Spring, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 38/21 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/15 (2015.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/212 (2013.01); A61K 35/15 (2013.01); A61K 38/1793 (2013.01); A61K 38/217 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); A61K 45/06 (2013.01);
Abstract

Methods and compositions are disclosed for treating a subject with a cancer. The compositions can include a chimeric molecule comprising an agent that specifically binds the interleukin 4 receptor (IL-4R) and a toxic moiety, an interferon alpha (IFNα), and an interferon gamma (IFNγ). In some non-liming embodiments, the compositions can also include monocytes. The methods disclosed herein include administering a therapeutically effective amount of the compositions taught herein to a subject with cancer, thereby treating the cancer in the subject, wherein cells in the cancer express IL-4R. In some non-liming embodiments, the methods can also include administering monocytes.


Find Patent Forward Citations

Loading…